LLY

1,037

+2.17%↑

JNJ

244.47

+1.48%↑

ABBV

227.53

+3.09%↑

NVS

160.86

+0.83%↑

MRK

119.17

-0.13%↓

LLY

1,037

+2.17%↑

JNJ

244.47

+1.48%↑

ABBV

227.53

+3.09%↑

NVS

160.86

+0.83%↑

MRK

119.17

-0.13%↓

LLY

1,037

+2.17%↑

JNJ

244.47

+1.48%↑

ABBV

227.53

+3.09%↑

NVS

160.86

+0.83%↑

MRK

119.17

-0.13%↓

LLY

1,037

+2.17%↑

JNJ

244.47

+1.48%↑

ABBV

227.53

+3.09%↑

NVS

160.86

+0.83%↑

MRK

119.17

-0.13%↓

LLY

1,037

+2.17%↑

JNJ

244.47

+1.48%↑

ABBV

227.53

+3.09%↑

NVS

160.86

+0.83%↑

MRK

119.17

-0.13%↓

Search

Certara Inc

Slēgts

SektorsVeselības aprūpe

6.67 -3.61

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

6.44

Max

7

Galvenie mērījumi

By Trading Economics

Ienākumi

3.5M

1.5M

Pārdošana

46K

105M

P/E

Sektora vidējais

102.429

121.746

Peļņas marža

1.458

Darbinieki

1,487

EBITDA

-6.5M

23M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt

Prognoze 12 mēnešiem

+61.37% upside

Dividendes

By Dow Jones

Nākamie ieņēmumi

2026. g. 26. febr.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

-737M

1.1B

Iepriekšējā atvēršanas cena

10.28

Iepriekšējā slēgšanas cena

6.67

Ziņu noskaņojums

By Acuity

50%

50%

160 / 352 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Very Strong Bearish Evidence

Certara Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 12. febr. 23:57 UTC

Karstas akcijas

Stocks to Watch: Applied Materials, Arista, DraftKings, Pinterest

2026. g. 12. febr. 23:35 UTC

Peļņas
Galvenie tirgus virzītāji

Arista Networks Surges on AI Networking Demand, Despite Rising Costs

2026. g. 12. febr. 23:28 UTC

Peļņas

Applied Materials Profit Rises on Soaring AI Demand -- Update

2026. g. 12. febr. 21:47 UTC

Peļņas

Vertex Pharmaceuticals Revenue Climbs on Continued Cystic Fibrosis Demand

2026. g. 13. febr. 00:00 UTC

Tirgus saruna

ANZ Gets a New Bull as Productivity Prospects Improve -- Market Talk

2026. g. 12. febr. 23:47 UTC

Tirgus saruna

Nikkei May Fall After AI Concerns Drag Stocks on Wall Street -- Market Talk

2026. g. 12. febr. 23:38 UTC

Tirgus saruna

Gold Steady; Could Undergo Technical Recovery -- Market Talk

2026. g. 12. febr. 23:33 UTC

Peļņas

Coinbase Swings to a Fourth-Quarter Loss Amid Crypto Meltdown -- 2nd Update

2026. g. 12. febr. 23:09 UTC

Tirgus saruna

South32's Hermosa Review Stokes Spending Fears -- Market Talk

2026. g. 12. febr. 22:55 UTC

Peļņas
Karstas akcijas

Applied Materials, DraftKings, Airbnb: Earnings in Focus -- WSJ

2026. g. 12. febr. 22:46 UTC

Tirgus saruna

Northern Star Outlook Needs Project Done On Time, In Budget -- Market Talk

2026. g. 12. febr. 22:23 UTC

Peļņas

Coinbase Swings to a Fourth-Quarter Loss Amid Crypto Meltdown -- Update

2026. g. 12. febr. 22:15 UTC

Peļņas

Agnico-Eagle Mines: Gold Production for 2026 and 2027, Expected at 3.3M to 3.5M Ounces Annually, Is Consistent With Previous Guidance, With Offsetting Adjustments Between Mine Sites >AEM.T

2026. g. 12. febr. 22:15 UTC

Peļņas

Agnico-Eagle Mines Raises Dividend to 45c >AEM.T

2026. g. 12. febr. 22:15 UTC

Peļņas

Agnico-Eagle Mines 4Q Rev $3.56B >AEM.T

2026. g. 12. febr. 22:15 UTC

Peļņas

Agnico-Eagle Mines 4Q EPS $3.04 >AEM.T

2026. g. 12. febr. 22:00 UTC

Peļņas

AGNICO EAGLE REPORTS FOURTH QUARTER AND FULL YEAR 2025 RESULTS - RECORD QUARTERLY AND ANNUAL FREE CASH FLOW; 2025 PRODUCTION GUIDANCE ACHIEVED; TOTAL 2025 SHAREHOLDER RETURNS OF $1.4 BILLION; DIVIDEND INCREASED BY 12.5%; UPDATED THREE-YEAR GUIDANCE >AEM.T

2026. g. 12. febr. 22:00 UTC

Peļņas

Agnico-Eagle Mines 4Q Rev $3.56B >AEM

2026. g. 12. febr. 22:00 UTC

Peļņas

Agnico-Eagle Mines 4Q Net $1.52B >AEM

2026. g. 12. febr. 22:00 UTC

Peļņas

Agnico-Eagle Mines 4Q Adj EPS $2.70 >AEM

2026. g. 12. febr. 22:00 UTC

Peļņas

AGNICO EAGLE REPORTS FOURTH QUARTER AND FULL YEAR 2025 RESULTS - RECORD QUARTERLY AND ANNUAL FREE CASH FLOW; 2025 PRODUCTION GUIDANCE ACHIEVED; TOTAL 2025 SHAREHOLDER RETURNS OF $1.4 BILLION; DIVIDEND INCREASED BY 12.5%; UPDATED THREE-YEAR GUIDANCE >AEM.T

2026. g. 12. febr. 22:00 UTC

Peļņas

Agnico-Eagle Mines 4Q EPS $3.04 >AEM

2026. g. 12. febr. 21:57 UTC

Peļņas

XP 4Q Rev BRL4.95B >XP

2026. g. 12. febr. 21:52 UTC

Peļņas

Coinbase Revenue Falls Short as Crypto Market Sags -- Barrons.com

2026. g. 12. febr. 21:50 UTC

Tirgus saruna

Tech, Media & Telecom Roundup: Market Talk

2026. g. 12. febr. 21:50 UTC

Tirgus saruna

Financial Services Roundup: Market Talk

2026. g. 12. febr. 21:50 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2026. g. 12. febr. 21:47 UTC

Peļņas

Morningstar 4Q Rev $641M >MORN

2026. g. 12. febr. 21:39 UTC

Peļņas

Coinbase Revenue Falls Short as Crypto Market Sags -- Barrons.com

2026. g. 12. febr. 21:38 UTC

Peļņas

Howmet Stock Jumps. Earnings Show Strength For This Sector. -- Barrons.com

Salīdzinājums

Cenas izmaiņa

Certara Inc Prognoze

Cenas mērķis

By TipRanks

61.37% augšup

Prognoze 12 mēnešiem

Vidējais 11.57 USD  61.37%

Augstākais 13 USD

Zemākais 9 USD

Pamatojoties uz 9 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Certara Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

9 ratings

6

Pirkt

3

Turēt

0

Pārdot

Tehniskais rādītājs

By Trading Central

11.27 / 12.79Atbalsts un pretestība

Īstermiņā

Very Strong Bearish Evidence

Vidējā termiņā

Very Strong Bullish Evidence

Ilgtermiņā

Strong Bullish Evidence

Noskaņojums

By Acuity

160 / 352 Rangs Veselības aprūpe

Ziņu noskaņojums

Neutral

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Vidējais

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Certara Inc

Certara, Inc., together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics. The company provides Simcyp Simulator, a mechanistic biosimulation platform mechanistic biosimulation investigational new drug and translational stages; Simcyp Biopharmaceutics, used to identify and refine drug formulations; and Simcyp Secondary Intelligence which integrates toxicology with quantitative analysis of networks of molecular and functional biological changes to identify drug toxicity and adverse drug reactions. In addition, it offers Phoenix WinNonlin, a platform for non-compartmental analysis, pharmacokinetic/pharmacodynamic, and toxicokinetic; phoenix hosted, that provides a secured and validated certara amazon web services workspace; Phoenix NLME, a population modeling and simulation software for nonlinear mixed effects models; and pirana modeling workbench. Further, the company provides pinnacle 21, a cloud-based platform for clinical data automation, standardization, and validation; Pinnacle 21 Data Exchange, used to define data standards and specifications; and Metadata Repository, to enable study design using controlled and standardized data. It serves life sciences companies, biopharmaceutical companies, research organizations, academic institutions, and global regulators, as well as animal health, crop science, bio science, medical devices, and public sector industries. Certara Inc. was founded in 2008 and is headquartered in Princeton, New Jersey.
help-icon Live chat